At ADLM 2025, Roche Diagnostics demonstrated their expertise in scientific leadership and innovative advancements.
Roche Showcases Innovative Diagnostics Solutions at ADLM 2025
Roche Diagnostics is making a significant impact at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo in Chicago, showcasing a range of key innovations across molecular diagnostics, clinical chemistry, immunoassay, and laboratory automation.
The company's presence at ADLM reflects its holistic approach to healthcare innovation, integrating powerful science with intelligent technologies to deliver timely, accurate, and integrated diagnostic solutions across diverse healthcare settings.
One of the main products on display is the cobas® liat system, a point-of-care PCR platform that delivers rapid results within 20 minutes. It offers a growing menu of CLIA-waived multiplex and singleplex assays, primarily targeting respiratory and sexual health diagnostics. This system brings gold-standard PCR technology closer to patient care settings.
Another innovation is the Future cobas® Mass Spec solution, a forthcoming end-to-end clinical mass spectrometry platform designed for seamless integration into routine laboratory workflows, enhancing clinical mass spectrometry testing capabilities.
The cobas® pure integrated solutions are platforms that combine clinical chemistry, immunoassay, and Ion-Selective Electrode (ISE) testing on a single system, targeted for low- to mid-volume lab settings. This consolidation of multiple test types simplifies diagnostics and enables operational efficiency.
The CCM Vertical modular system is a flexible, space-efficient system that integrates into existing cobas connection modules, enabling enhanced laboratory workflow and space optimization.
The cobas® eplex system is a rapid syndromic molecular diagnostic solution offering test panels for respiratory and bloodstream infections. It integrates processing from order to report, streamlining workflow and turnaround times.
The cobas® 6800/8800 Systems version 2 are updated molecular diagnostic platforms with enhanced usability and efficiency. The update includes optimized software for existing systems and a new model to support lab workflows better.
The LightCycler® PRO is a quantitative PCR (qPCR) system designed to provide accurate and flexible solutions for research and clinical diagnostic labs, featuring an improved user experience.
Roche is also emphasizing its digital transformation via AI-powered solutions and expanded healthcare partnerships enabled by the navify® digital solutions platform. These initiatives aim to improve laboratory efficiency and patient outcomes.
In addition, Roche is highlighting innovations in cardiovascular risk assessment (notably Lipoprotein(a) testing) and cervical cancer screening at the event, reflecting a broad portfolio of diagnostic applications.
The cobas® reagent portfolio offers the broadest menu on an integrated platform and includes the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays, aiming to more effectively detect amyloid pathology and support an Alzheimer's disease diagnosis.
Roche is committed to sustainability, having been an integral part of its business for over 125 years. The company is a pioneer in personalized healthcare and aims to further transform how healthcare is delivered.
For more information about Roche and its innovations, visit www.roche.com. Roche will be located at Booth 1902 at ADLM. The company is also hosting two expert-led workshops at the event: "Cardiovascular Risk Assessment and Lipoprotein(a): Closing Gaps in ASCVD Prevention" and "Innovations in Cervical-Cancer Screening and Diagnosis".
[1] Roche Diagnostics. (2025). Roche Diagnostics Showcases Innovations at ADLM 2025. Retrieved from www.roche.com/diagnostics/news/adlm-2025-innovations
[2] Roche Diagnostics. (2025). Roche Diagnostics Highlights Digital Transformation at ADLM 2025. Retrieved from www.roche.com/diagnostics/news/adlm-2025-digital-transformation
[3] Roche Diagnostics. (2025). Roche Diagnostics Emphasizes Sustainability at ADLM 2025. Retrieved from www.roche.com/diagnostics/news/adlm-2025-sustainability
[4] Roche Diagnostics. (2025). Roche Diagnostics Spotlights Cardiovascular Risk Assessment and Cervical Cancer Screening at ADLM 2025. Retrieved from www.roche.com/diagnostics/news/adlm-2025-cardiovascular-cervical-cancer
- Leveraging its integrated healthcare solutions, Roche Diagnostics is demonstrating advances in both medical-conditions diagnostics, such as the cobas® liat system for respiratory and sexual health, and health-and-wellness screening, like the Lipoprotein(a) testing for cardiovascular risk assessment.
- Moving beyond lab innovation, Roche is advocating for the implementation of technology across the diagnostics landscape, with digital transformations via AI-powered solutions like the navify® platform and the adoption of cutting-edge technology like the forthcoming Future cobas® Mass Spec solution for clinical mass spectrometry.
